Project Grant R01AI194343
Award Date 9/12/25
Completion Date 8/31/30
Dollars Obligated $395K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Australia
Similar Awards
- This $118,488 Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) on January 20, 2025, supports research to develop HIV-resistant hematopoietic stem cells through targeted base editing. The project aims to identify genetic mutations in the CCR5 and CXCR4 co-receptors that can prevent HIV entry into CD4 cells while maintaining the central functions of these proteins in hematopoiesis. The research involves...
- This $624,902 Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to investigate the impact of the HIV accessory protein Vpr on epigenetic remodeling and viral persistence in myeloid cells. The 5-year project, starting on Apr 23, 2025, will focus on characterizing how Vpr induces epigenetic changes to facilitate sustained HIV transcription and latency reactivation, as well as...
- This Project Grant award of $486,057 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of a multipronged mRNA gene therapy approach to address challenges in achieving an HIV cure. The award aims to develop three novel mRNA-based interventions: targeted delivery of the viral protein Tat to activate HIV transcription, hepatic delivery of mRNA encoding HIV-neutralizing...
- This Project Grant award for $3,643,653.00, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research (CFDA 93.855) program, aims to generate a chimeric antigen receptor (CAR) approach that can control HIV viral replication and eliminate the viral reservoir. The award supports four key projects: Engineering viral-specific T cells with improved function and persistence for chronic HIV infection (Project 1). Developing an...
- This Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to investigate the dynamics and evolution of HIV Gag and GagPol processing. The $752,745 award aims to use molecular dynamics simulations, single-molecule FRET imaging, and cryo-electron tomography to probe the structure and dynamics of Gag and GagPol that enable ordered processing by the viral...
- This Project Grant award of $800,389.00 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to evaluate the safety and therapeutic potential of a novel strategy towards a cure for HIV infection. The proposed treatment combines soluble IL-15/IL-15RA-FC with a TGF-β pathway blockade and therapeutic vaccination to enhance and restore anti-viral immunity, leading to sustained viral remission...
- This $197,366 Project Grant was awarded on March 1, 2025 by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The project aims to identify the molecular mechanisms that control the natural, immune-mediated restriction of X4-tropic HIV virus, which typically emerges only in late-stage HIV disease when the immune system is impaired. The research will utilize primary CD4 T cells, in vivo analyses in...
- This $147,486 Project Grant was awarded on January 10, 2025 by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855). The grant supports research by Case Western Reserve University to investigate how the N6-methyladenosine (m6A) RNA modification affects the post-transcriptional processing of human immunodeficiency virus (HIV) transcripts. The research aims to elucidate the role of m6A in the...
- The University of Chicago was awarded a $295,276 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855), to computationally investigate key morphological transitions in the HIV-1 life cycle. The research aims to develop a mechanistic understanding of viral assembly, maturation, and uncoating processes, which could aid in the design of new antiretroviral therapies targeting...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), is providing $919,501 to Emmune Inc. to develop a non-viral gene therapy platform using ECD4-IG, an antibody-like therapeutic protein, to suppress HIV replication for a lifetime after a single intramuscular injection. The goal is to achieve a functional cure for HIV by sustaining therapeutically-effective plasma...